Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Orthopedics
Volume 2014 (2014), Article ID 452418, 4 pages
http://dx.doi.org/10.1155/2014/452418
Case Report

Bilateral Atypical Femoral Fractures in a Patient with Multiple Myeloma Treated with Intravenous Bisphosphonate Therapy

Department of Orthopedics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan

Received 16 May 2014; Accepted 16 July 2014; Published 22 July 2014

Academic Editor: Sungtaek Jung

Copyright © 2014 Ichiro Tonogai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. Kyle and S. V. Rajkumar, “Treatment of multiple myeloma: a comprehensive review.,” Clinical lymphoma & myeloma, vol. 9, no. 4, pp. 278–288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Kyle, “Multiple myeloma: review of 869 cases,” Mayo Clinic Proceedings, vol. 50, no. 1, pp. 29–40, 1975. View at Google Scholar · View at Scopus
  3. R. Fonseca, M. C. Trendle, T. Leong et al., “Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients,” British Journal of Haematology, vol. 109, no. 1, pp. 24–29, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Abildgaard, K. Brixen, J. E. Kristensen, E. F. Eriksen, J. L. Nielsen, and L. Heickendorff, “Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy,” British Journal of Haematology, vol. 120, no. 2, pp. 235–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Terpos, J. F. Apperley, D. Samson et al., “Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients,” Bone Marrow Transplantation, vol. 31, no. 3, pp. 163–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. V. Odvina, J. E. Zerwekh, D. S. Rao, N. Maalouf, F. A. Gottschalk, and C. Y. C. Pak, “Severely suppressed bone turnover: a potential complication of alendronate therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1294–1301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Y. Park-Wyllie, M. M. Mamdani, D. N. Juurlink et al., “Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women,” Journal of the American Medical Association, vol. 305, no. 8, pp. 783–789, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Berenson, L. Rajdev, and M. Broder, “Bone complications in multiple myeloma,” Cancer Biology and Therapy, vol. 5, no. 9, pp. 1082–1085, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Terpos, O. Sezer, P. I. Croucher et al., “The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network,” Annals of Oncology, vol. 20, no. 8, pp. 1303–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Abe, “Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma,” International Journal of Hematology, vol. 94, no. 4, pp. 334–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Green, “Bisphosphonates: preclinical review,” Oncologist, vol. 9, no. 4, pp. 3–13, 2004. View at Google Scholar · View at Scopus
  12. M. C. Winter, I. Holen, and R. E. Coleman, “Exploring the anti-tumour activity of bisphosphonates in early breast cancer,” Cancer Treatment Reviews, vol. 34, no. 5, pp. 453–475, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. R. Allen, H. Follet, M. Khurana, M. Sato, and D. B. Burr, “Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib,” Calcified Tissue International, vol. 79, no. 4, pp. 255–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. Neviaser, J. M. Lane, B. A. Lenart, F. Edobor-Osula, and D. G. Lorich, “Low-energy femoral shaft fractures associated with alendronate use,” Journal of Orthopaedic Trauma, vol. 22, no. 5, pp. 346–350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Grasko, R. P. Herrmann, and S. D. Vasikaran, “Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 3, pp. 645–649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. E. Puhaindran, A. Farooki, M. R. Steensma, M. Hameed, J. H. Healey, and P. J. Boland, “Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates,” Journal of Bone and Joint Surgery A, vol. 93, no. 13, pp. 1235–1242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. T. Chang, A. S. Tenforde, C. D. Grimsrud et al., “Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy,” Bone, vol. 51, no. 3, pp. 524–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Fleisch, “Bisphosphonates: mechanisms of action and clinical use in osteoporosis—an update,” Hormone and Metabolic Research, vol. 29, no. 3, pp. 145–150, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. R. A. Kyle, G. C. Yee, M. R. Somerfield et al., “American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma,” Journal of Clinical Oncology, vol. 25, no. 17, pp. 2464–2472, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. W. Nieves and F. Cosman, “Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates,” Current Osteoporosis Reports, vol. 8, no. 1, pp. 34–39, 2010. View at Publisher · View at Google Scholar · View at Scopus